CRINETICS PHARMACEUTICALS INC (CRNX)
Health Care · Biotechnology · NASDAQ
Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors.
What CRINETICS PHARMACEUTICALS INC does
Crinetics Pharmaceuticals is a clinical-stage precision medicine company focused on the discovery and development of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's platform is built around the discovery of small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its pipeline includes therapeutics for conditions such as acromegaly, Cushing’s disease, and congenital adrenal hyperplasia.
Themes: rare disease therapies, endocrine system disorders, precision medicine, drug discovery and development
Fundamentals
- Price$84.69 as of 2026-08-21 close
- Market cap$9.0B as of 2026-08-21
- 1-year return+188.1% 2025-08-21 close $29.40 → 2026-08-21 close $84.69
- P/En/a negative earnings
- Net margin-1189.9% as of 2026-08-24
- Gross margin+86.0% as of 2026-08-24
- ROE-44.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+640.7% FY2025 vs FY2024, SEC XBRL
- Beta0.02 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How CRNX compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CRNX is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
46.4 #1034 of 1,704 scored · #178 of 240 in Health Care
Trend 78th: a strong uptrend, with buyers in control; catalysts 58th: open-market insider buys in 90 days 21, the analyst consensus rating is unchanged since the prior reading; weakest is momentum 30th: its RSI momentum gauge is overbought (a stretched reading). Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How CRINETICS PHARMACEUTICALS INC looks technically
CRINETICS PHARMACEUTICALS INC (CRNX) is trading 71.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 27 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 80, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 90, in overbought territory (above 70). It made a new 20-day high about 5 trading days ago. It is trading at or near its all-time high.
Trend
8
| Distance from the 200-day | it is trading 71.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +71.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $68.85 | $68.85 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $49.33 | $49.33 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 25 calendar days ago — the swings before that are what the structure reading is measured on | 25 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 27 trading days ago — a "golden cross", a bullish long-term signal | 27 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 71.7% above | +71.7% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 80, with buyers in control | 80.3 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 90, in overbought territory (above 70) | 90.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($83.75 to $84.80) — its "stochastic" reading is 90 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 90.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 21 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $84.80 | $84.80 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.1% |
| Above the 52-week low | it is 194.8% above its 52-week low (its lowest price of the past year) | +194.8% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.1% |
| Since a 20-day breakout | it made a new 20-day high about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day high about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $84.80 (set on 2026-08-18) | $84.80 |
| Given back of the 52-week move | over the past year its closes ranged ($29.09 to $84.75), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $48.57 to $50.35. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.1% |
| From the all-time high | it is trading at or near its all-time high | -0.1% |
| Nearest price level | it is trading 1.1% above a support level at $83.73 — a price it turned at twice since 2026-07-27, most recently on 2026-07-31. Since 2024-08-21 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.1% |
| All-time low | its lowest closing price on record is $10.63 (set on 2020-03-17) | $10.63 |
| Above the all-time low | it is 696.7% above its all-time low | +696.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 89% of it) | 11th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5956 between its high and its low — about 0.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5956 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $83.39 and $85.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $83.39 – $84.20 – $85.01 |
| Typical daily range (% of price) | its price moves about 0.7% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 0.7% |
| Stretch from the 200-day average | it is trading 59.4 daily ranges above its 200-day average price (71.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale. Read that multiple with care: this company's daily range is unusually small (about 0.7% of its price), which is what makes the multiple large — a stock trading in a narrow band near a takeover price does this | 59.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.60× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.0% |
|---|---|---|
| Open gap | it gapped 98.9% above the previous close 33 sessions ago and has not traded back through the level it left behind at 42.03 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +98.9% |
| Gap filled | a 2.8% gap up opened on 2026-06-11 has been "filled" 49 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 49 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.4 percentage points (the stock gained 0.9% while the market gained 2.3%) | -1.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 125.2 percentage points (the stock gained 128.3% while the market gained 3.1%) | +125.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 83.9 percentage points (the stock gained 95.0% while the market gained 11.1%) | +83.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 167.6 percentage points (the stock gained 188.1% while the market gained 20.5%) | +167.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 40% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.8% of the share price. | +40.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 29% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $65.75 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +28.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $84.41 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +0.3% |
Price levels it has turned at before
CRNX last closed at $84.69 on 2026-08-21. Since 2024-08-21 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $83.73 | Support | 1.1% below the last close | turned there twice · 2026-07-27 to 2026-07-31 |
| $60.19 | Support | 28.9% below the last close | turned there twice · 2024-10-22 to 2024-12-11 |
| $55.39 | Support | 34.6% below the last close | turned there three times · 2024-08-28 to 2024-10-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.86 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$85.50 range $85.00 – $90.00; median $85.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CRNX
- Consensus EPS estimate-$1.07 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has a history of losses, is currently unprofitable, and expects to continue to incur significant expenses as it advances its clinical pipeline.","Dependence on the success of its lead product candidates for the treatment of rare endocrine diseases.","Risks associated with the regulatory approval process and potential difficulties in commercializing new pharmaceutical products."]
What changed in the latest 10-Q
AI-assisted comparison of CRNX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing: Recent Developments section with specific Q1 2026 metrics (232 Enrollment Forms, 263 unique HCPs, 70% reimbursed therapy)
- In newer filing: CHMP positive opinion and EC approval of PALSONIFY in April 2026
- In newer filing: MAA submission to Brazil's ANVISA in March 2026
- In newer filing: SKK NDA submission in Japan in April 2026
- In newer filing: January 2026 Atumelnant update with fourth cohort data and OLE study data
- In newer filing: BALANCE-CAH first participant dosed in January 2026
- In newer filing: EQUILIBRIUM Phase 2/3 study design announced in February 2026, first participant expected Q2 2026
- In newer filing: Financial operations overview section explaining transition from clinical to commercial stage
- In newer filing: Statement that comparison methodology changed to include sequential quarter comparisons alongside year-over-year
- In newer filing: Three-column financial comparison table (Q1 2026, Q4 2025, Q1 2025) with specific revenue and expense figures
- Removed:
- In older filing: Reference to 'our Annual Report on Form 10-K for the year ended December 31, 2024' replaced with 'FY 2025 Form 10-K'
- In older filing: Mention of 'the impact of international conflicts' as a forward-looking statement topic (not present in newer)
- In older filing: 'Key Pipeline Updates' section title replaced with 'Recent Developments' in newer filing
- In older filing: Detailed market size analysis (36,000 acromegaly patients, 17,000 undiagnosed, etc.) not repeated in newer filing
- In older filing: Details on CALM-CAH Phase 3 study design (not mentioned in newer filing's comparable section)
- In older filing: CRN09682, CRN12755, CRN10329 early-stage pipeline details and R&D Day presentation information (truncated in older text but substantially less detail in newer)
- In older filing: BALANCE-CAH planned Q4 2025 initiation statement (newer shows it already started in January 2026)
- Reworded:
- Newer: Forward-looking statements reference 'FY 2025 Form 10-K' vs. older 'Annual Report on Form 10-K for the year ended December 31, 2024'
- Newer: Overview section expanded with phrase 'committed to transforming the treatment' and 'science rooted in patient needs' vs. older 'focused on the discovery, development and commercialization'
- Newer: Overview describes expertise as 'targeting GPCRs with small molecules that have specifically tailored pharmacology and properties' vs. older 'extensive expertise in endocrine G protein coupled receptors, or GPCRs'
- Newer: PALSONIFY description changed from 'under review by regulatory agencies in Europe' to specific approvals (CHMP positive opinion April 2026, EC approval April 2026)
- Newer: Paltusotine carcinoid syndrome development not mentioned (older filing referenced it under clinical development)
- Newer: Results of Operations section explains new comparison methodology: 'we compare our results of operations for the current quarter to the immediately preceding fiscal quarter and the same period from the previous fiscal year'
- Notes:
- Older filing text appears truncated at end of Early-Stage Pipeline section ('The R&D Day presentation included the followin'), making complete comparison of that section impossible
- Comparison spans different fiscal periods (Q1 2026 vs. Q3 2025 in filings), which affects relevance of some pipeline updates
- Newer filing focuses on recent commercialization progress while older filing was filed during pre-approval phase, creating inherent structural differences
Risk Factors
- Added:
- Newer filing (2026-05-07) includes product revenue of $10,306 thousand for Q1 2026, which did not exist in older filing
- Newer filing includes cost of product revenue of $200 thousand for Q1 2026
- Newer filing shows trade accounts receivable of $5,683 thousand at March 31, 2026, absent from older filing's balance sheet
- Newer filing shows inventory of $3,064 thousand at March 31, 2026, absent from older filing's balance sheet
- Newer filing includes issuance of common stock transaction with net proceeds of $379,771 thousand during Q1 2026
- Newer filing shows common stock shares outstanding increased to 105,314 shares at March 31, 2026 from 95,575 at December 31, 2025
- Removed:
- Older filing showed equity method investment loss line item; not present in newer filing
- Older filing presented nine-month and quarterly comparative data; newer filing presents only quarterly data for three months ended March 31
- Reworded:
- Newer filing statement of operations caption changed from 'Revenues' to 'Total revenue' with breakdown between 'Product revenue, net' and 'Collaboration and license revenue'
- Newer filing states 'Loss from operations' instead of 'Loss before equity method investment' as intermediate line item
- Newer filing includes 'Unrealized gain (loss) on investment securities' line in comprehensive income calculation; older filing used 'Unrealized gain on investment securities'
- Notes:
- The filings cover different fiscal periods (Q1 2026 vs. nine months ended September 30, 2025), limiting direct period-to-period comparisons
- Older filing presented both quarterly and year-to-date results; newer filing presents only quarterly results
- Balance sheet dates differ between filings (March 31, 2026 vs. September 30, 2025), making balance sheet comparisons reflect period-specific timing
- The presence of product revenue in newer filing versus absence in older filing may reflect operational milestones rather than accounting changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 3 sells ($366143) — 2 selling insiders
- Last 180 days0 buys · 6 sells ($4M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-02. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CRNX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for CRNX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding CRNX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 26,987,794
- Reported value $980,196,686
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CRNX had 5,866,425 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CRNX had 5.53% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.78 days to cover at the same settlement.
- Reported short interest (shares) 5,866,425
- Short interest (% of shares outstanding) 5.53%
- Prior settlement (shares) 6,212,042
- Reported change -5.56%
- Days to cover (reported) 1.78
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ipsen (IPSEY)
- Novartis (NVS)
- Pfizer (PFE)
- Recordati S.p.A.
- Amryt Pharma (acquired by Chiesi)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CRNX vs…
CRINETICS PHARMACEUTICALS INC is found in…
Frequently asked questions
What does CRINETICS PHARMACEUTICALS INC (CRNX) do?
Crinetics Pharmaceuticals is a clinical-stage precision medicine company focused on the discovery and development of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's platform is built around the discovery of small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its pipeline includes therapeutics for conditions such as acromegaly, Cushing’s disease, and congenital adrenal hyperplasia.
What sector is CRINETICS PHARMACEUTICALS INC (CRNX) in?
CRINETICS PHARMACEUTICALS INC (CRNX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are CRINETICS PHARMACEUTICALS INC's (CRNX) competitors?
Notable peers of CRINETICS PHARMACEUTICALS INC (CRNX) include Ipsen, Novartis, Pfizer, Recordati S.p.A. and Amryt Pharma (acquired by Chiesi). This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in CRNX?
Yes — we hold 4 matched STOCK Act disclosures for CRNX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is CRINETICS PHARMACEUTICALS INC (CRNX) overbought or oversold right now?
CRINETICS PHARMACEUTICALS INC (CRNX) is currently in overbought territory (its 14-day RSI is 90, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CRNX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.